MahranShoukierMD

Internal Medicine • Houston, TX

Hospital Medicine/Hospitalist, Hematology/Oncology

Physician

Join to view full profile

Dr. Shoukier is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shoukier's full profile

Already have an account?

Office
2130 W Holcombe Blvd
Fl 10
Houston, TX 77030
Phone+1 713-600-0900

Fax+1 713-600-0070

Education & Training

Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2020 - 2023
St Barnabas HospitalResidency, Internal Medicine, 2012 - 2015
Damascus University Faculty of MedicineClass of 2004

Certifications & Licensure

TX State Medical License 2016 - 2026
VA State Medical License 2015 - 2026
NC State Medical License 2015 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

5 citations
Representation of the population in need for pivotal clinical trials in lymphomas.
Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K M Islam
Blood. 2023-08-31
43 citations
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy
Sangeetha Venugopal, Mahran Shoukier, Marina Konopleva, Courtney D. DiNardo, Farhad Ravandi
Cancer. 2021-10-01
13 citations
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Jayastu Senapati, Mahran Shoukier, Guillermo Garcia-Manero, Xuemei Wang, Keyur Patel
American Journal of Hematology. 2022-05-01

Lectures

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
2019 ASCO Annual Meeting - 6/1/2019
Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.
2019 ASCO Annual Meeting - 6/1/2019